UK researchers sourcing Retatrutide: this page is your complete laboratory reference — dosage protocols used in published trials, HPLC purity standards, COA expectations, reconstitution, and UK regulatory context. For the broader mechanism and clinical-evidence overview, see our Retatrutide UK Complete Research Guide 2026.
Ready to order research material? Buy HPLC-tested Retatrutide (≥99% purity, UK-shipped, per-batch COA) from Peptides Lab UK.
Quick Answer: UK-based researchers sourcing Retatrutide (LY3437943) for investigational laboratory work should verify HPLC purity ≥99%, obtain a batch-specific Certificate of Analysis (COA), follow the dose-escalation schedules published in the Phase 2 NEJM trial (Jastreboff et al., 2023), and document bona fide research purpose under UK regulatory expectations. This guide consolidates every protocol, sourcing checkpoint, and compliance consideration into one reference.
Retatrutide (LY3437943): Research Compound Overview
Retatrutide, also known by its Eli Lilly development code LY3437943, is an investigational triple-receptor agonist that simultaneously activates the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple-agonism mechanism is the pharmacological foundation that distinguishes Retatrutide from earlier single-receptor compounds (such as semaglutide) and dual-receptor compounds (such as tirzepatide). For the complete clinical-evidence and mechanism overview, read the Retatrutide UK Complete Research Guide 2026. This page focuses specifically on the research-operations dimension: dosing protocols, sourcing verification, reconstitution, storage, and UK compliance.
Published Retatrutide Dosage Protocols
The only peer-reviewed dosage protocols in the public record for Retatrutide come from the Phase 1 and Phase 2 clinical trials conducted by Eli Lilly. UK researchers should reference these exactly and not extrapolate beyond what has been published.
Phase 2 Obesity Trial Dose-Escalation Schedule
Published in the New England Journal of Medicine in June 2023 (Jastreboff AM, et al., PMID 37369579), the Phase 2 trial used once-weekly subcutaneous administration with stepwise dose escalation. The protocol enrolled 338 adults with obesity across five maintenance-dose cohorts (1 mg, 4 mg, 8 mg, and 12 mg) plus placebo. The 12 mg cohort titrated through 2 mg → 4 mg → 8 mg at four-week intervals before reaching the maintenance dose. Key reported outcomes at 48 weeks:
- 1 mg weekly: ~8.7% mean body weight reduction
- 4 mg weekly: ~17.1% mean body weight reduction
- 8 mg weekly: ~22.8% mean body weight reduction
- 12 mg weekly: ~24.2% mean body weight reduction
- Placebo: ~2.1% mean body weight reduction
Full details are available in the primary publication (DOI: 10.1056/NEJMoa2301972). Researchers designing protocol analogues should reference the NEJM paper directly.
Phase 2 Type 2 Diabetes Trial (TRANSCEND-T2D)
A parallel Phase 2 trial in adults with type 2 diabetes used similar dose-escalation to 4 mg, 8 mg, and 12 mg weekly maintenance doses. Published results (Rosenstock J, et al., The Lancet, 2023) reported HbA1c reductions of up to 2.02% and body weight reductions of up to 16.9% at 36 weeks across the investigated doses.
Retatrutide Reconstitution Protocol for Research Use
Research-grade Retatrutide is supplied in lyophilised (freeze-dried) form and must be reconstituted before laboratory use. Reconstitution procedures are standard across research-grade peptides in this class.
Reconstitution — Step-by-Step
- Allow the lyophilised vial to reach room temperature (15–25°C) before opening.
- Select diluent — bacteriostatic water for injection (BWFI) is preferred for multi-use vials; sterile water for injection (SWFI) is appropriate for single-use reconstitution.
- For a 10 mg vial and a target concentration of 5 mg/mL, draw 2 mL of diluent into a sterile syringe. For 10 mg/mL, draw 1 mL.
- Inject the diluent slowly down the inside wall of the vial — do not direct the stream onto the lyophilised powder.
- Gently swirl until fully dissolved. Do not shake vigorously.
- Label the vial with reconstitution date, concentration, and expiry (4–6 weeks under refrigeration).
- Store at 2–8°C, protected from light.
Reconstitution Volume Reference
For a 10 mg vial:
- 1 mL diluent → 10 mg/mL final concentration (10 IU on a U100 insulin syringe = 1 mg)
- 2 mL diluent → 5 mg/mL final concentration (20 IU on a U100 insulin syringe = 1 mg)
- 5 mL diluent → 2 mg/mL final concentration (50 IU on a U100 insulin syringe = 1 mg)
For the corresponding Tirzepatide and Semaglutide reconstitution and dosing references, see our Tirzepatide UK Complete Research Guide and Semaglutide product page.
HPLC Purity and Certificate of Analysis (COA) Standards
Purity verification is the single most important quality control step in research peptide sourcing. UK researchers should accept nothing less than the following:
Minimum COA Requirements
- HPLC purity ≥99% — reverse-phase HPLC with clear chromatogram
- Mass spectrometry confirmation — MS result matching the theoretical molecular weight of Retatrutide (4731.6 Da)
- Batch number — must match the vial label
- Testing laboratory details — independent third-party lab, with accreditation or contact information
- Date of analysis — within a reasonable timeframe of manufacture
- Identity confirmation — compound name, CAS identifier (where applicable), sequence confirmation
- Impurity profile — any detected impurities characterised
Red Flags in COA Documentation
- Generic or template COAs that do not reference a specific batch number
- Absence of HPLC chromatogram or mass spectrometry data
- Testing performed only in-house by the supplier with no third-party verification
- Purity figures rounded to ≥95% or ≥97% rather than specific independent measurements
- Missing testing laboratory identification or contact
Peptides Lab UK publishes per-batch COAs with independent third-party HPLC and MS data on every product listing, including Retatrutide.
UK Regulatory Context: Research-Only Status
Retatrutide is not approved for human use by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the US Food and Drug Administration (FDA), or the European Medicines Agency (EMA). Its sole legitimate purchase pathway in the UK is for laboratory research use only.
What “Research Only” Means in UK Practice
- Retatrutide may be purchased and possessed for bona fide in vitro, in vivo (animal), or analytical research
- It must not be administered to humans for therapeutic, cosmetic, or recreational purposes
- Supply or distribution for human consumption may constitute an offence under the Human Medicines Regulations 2012
- Research buyers should retain records demonstrating legitimate scientific purpose — institutional affiliation, research project reference, or laboratory documentation
- Suppliers labelling or marketing investigational peptides for human use violate UK law and should be avoided
For a wider UK legal overview of research peptides, see our companion article Is Tirzepatide legal in the UK? (the legal framework is identical).
Storage and Stability
| State | Temperature | Duration |
|---|---|---|
| Lyophilised, long-term | -20°C (frozen), dark | 12–24 months |
| Lyophilised, short-term | 2–8°C (refrigerated) | 30–60 days |
| Reconstituted | 2–8°C (refrigerated) | 4–6 weeks |
| Room temperature (transit) | 15–25°C | Minimise duration |
Avoid repeated freeze-thaw cycles of reconstituted solution — each cycle introduces degradation risk via aggregation and cleavage, which compromises both purity and research reproducibility.
UK Supplier Due Diligence Checklist
Before purchasing Retatrutide from any UK supplier, verify every item on this list:
- Independent HPLC COA — batch-specific, third-party, ≥99% purity
- Mass spectrometry verification — MW confirmation of identity
- UK-based fulfilment — registered UK company address, UK shipping
- Research-only labelling — clear “for research purposes only / not for human consumption” disclaimers
- Transparent company information — Companies House registration visible; real contact details
- Cold-chain considerations — packaging appropriate for peptide stability in transit
- Professional website and documentation — no typos, no vague sourcing claims, no “legal grey area” language
- Customer reviews and verified feedback — ideally on independent platforms
Related Retatrutide Research
- Retatrutide UK Complete Research Guide 2026 — full pillar (mechanism, clinical data, regulatory overview)
- Retatrutide vs Tirzepatide: Head-to-Head Research Comparison
- How does retatrutide work?
- What is retatrutide used for?
- How much weight can you lose on Retatrutide?
- Does Retatrutide cause weight loss?
- Is Retatrutide a GLP-1 receptor agonist?
- What results can I expect from Retatrutide?
Frequently Asked Questions
What dosage was used in the Phase 2 Retatrutide clinical trial?
The Phase 2 trial (Jastreboff et al., NEJM 2023) used a dose-escalation protocol across five cohorts. The highest maintenance dose studied was 12 mg once weekly, reached through a step-up schedule beginning at 2 mg weekly and increasing at four-week intervals.
How is Retatrutide reconstituted for research use?
Lyophilised Retatrutide is typically reconstituted with bacteriostatic water or sterile water for injection. A common reconstitution for a 10 mg vial is 1 mL (10 mg/mL) or 2 mL (5 mg/mL). Reconstituted solution should be refrigerated and used within 4–6 weeks.
What HPLC purity standard should research-grade Retatrutide meet?
Research-grade Retatrutide should be independently HPLC-tested to at least 99% purity, with mass spectrometry confirming molecular weight. UK researchers should insist on a batch-specific COA.
Is Retatrutide legal to purchase for research in the UK?
Retatrutide is legal to purchase in the UK for bona fide laboratory research purposes only. It is not licensed by the MHRA for human use and must not be administered to humans or supplied for self-administration.
How should Retatrutide be stored?
Lyophilised at -20°C long-term or 2–8°C short-term, protected from light. Once reconstituted, 2–8°C for 4–6 weeks. Avoid freeze-thaw cycles.
What should a reliable UK Retatrutide supplier provide?
Batch-specific HPLC COA (≥99%), independent third-party verification, MS identity confirmation, clear research-only labelling, UK-based fulfilment with cold-chain consideration, and transparent company details.
Source Research-Grade Retatrutide in the UK
Peptides Lab UK supplies independently HPLC-tested Retatrutide (≥99% purity, per-batch COA, UK-shipped) for laboratory research use only. View the Retatrutide product listing and current COA, or start with the Retatrutide UK Complete Research Guide for mechanism, clinical data, and comparison context.
For research purposes only / not for human consumption.
